The International Vaccine Institute (IVI) is holding the 22nd International Vaccinology Course in September. The event will focus on vaccinology lessons from the COVID-19 pandemic. 

The 5-day training course features lectures, interactive case studies, and site visits presented and facilitated by experts from academia, industry, government, and nongovernmental organizations.

From vaccinology essentials to applied topics in vaccine discovery, development, and delivery, the course provides a comprehensive overview of vaccinology with a focus on practicality and innovation. There will also be dedicated sessions for networking and receiving feedback on current work projects. A preliminary agenda is available here.

Established in 2000, the course is one of the longest running vaccinology courses in the Asia–Pacific region. It aims to build knowledge and practical skills related to the science of vaccines and targets vaccine professionals from low- and middle-income countries. The event features world-renowned experts from various fields in vaccinology, immunology, and epidemiology, among others, as faculty members. Like the previous year, the course will be hosted at a partner site in Stockholm, Sweden—Karolinska Institutet—in addition to the flagship venue in Seoul.

Register for the 22nd International Vaccinology Course at IVI in Seoul, Republic of Korea
Participants will have the opportunity to attend the course at IVI’s headquarters on the campus of Seoul National University. All vaccinology fellows are invited to the Seoul location. Register for Seoul

IVI is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health. IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more.

IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO prequalification safety review. For more information, visit https://www.ivi.int.